share_log

复旦张江自愿披露关于注射用FZ-AD005抗体偶联剂用于治疗晚期实体瘤Ⅰ期临床试验完成首例受试者入组的公告

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd voluntarily disclosed the announcement of completing the first subject enrollment in Phase I clinical trial for injection of FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.

SZSI ·  Jul 24
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more